Shots: Exscientia to receive ~$50M as up front, ~$125M as milestones and additional clinical, regulatory, and commercial milestones of over $1.2B along with royalties on net sales of any marketed […]readmore
Tags : Exscientia
Evotec and Exscientia Initiate Human Clinical Trials of their Novel Immuno-Oncology Drug Published: Apr 9, 2021 | Tags: Evotec and Exscientia, Initiate, Human Clinical Trials, Novel, Immuno-Oncology Drug PlantForm Signs […]readmore
Shots: Exscientia to get up to $266.2M including upfront, research payments and clinical milestones plus royalties on sales. Bayer to get rights for the developed therapies under collaboration The […]readmore
Shots: Celgene & Exscientia enter into a 3yrs. partnership to accelerate the development of small molecules for three therapeutic programs for Celgene using Exscientia’s Centaur Chemist AI drug discovery platform […]readmore